NCT07332260RecruitingPhase 1
Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study
Alzheimer's Disease and Faecal Microbiota Transplantation
Source: ClinicalTrials.gov · Last updated 22 Apr 2026
Brief summary (registry, in English)
The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- May 2026
- Primary completion date
- Oct 2026
- Lead sponsor
- University Hospital of North Norway
- Diseases
- Alzheimer disease
- NCT number
- NCT07332260
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From May 2026 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving biological/antibody treatment
Other illness
- History of seizure disorder
- History of brain tumour or intracranial bleed
- Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder
- Decompensated heart disease
- Malignancy
- Inflammatory bowel disease
Other
- Contraindications for colonoscopy examination
- Contraindications for Magnetic Resonance Imaging (MRI)
- Life expectancy \< 1 year
- Clinical frailty scale 7 or more
- Alcohol or substance abuse
- Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin)
- Pregnant or planning pregnancy
- Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy
- Status after colectomy or hemicolectomy
- Immunocompromised individual
Who the study is looking for
- Alzheimer's dementia mild to moderate stage
- Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024)
- Capable of giving informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of North Norway, Tromsø Coordinator of this site? Confirm its status | Tromsø | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.